Is LDL-C passed its prime? The emerging role of Non-HDL, LDL-P, and ApoB in CHD risk assessment

被引：17

作者：

Davidson, Michael H. ^{[1
]}

机构：

[1] Univ Chicago, Pritzker Sch Med, Chicago, IL 60654 USA

来源：

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2008年 / 28卷 / 09期

关键词：

D O I：

10.1161/ATVBAHA.108.172718

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1582 / 1583

页数：2

共 12 条

[1] Effects of torcetrapib in patients at high risk for coronary events [J].

Barter, Philip J. ;

Caulfield, Mark ;

Eriksson, Mats ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Mosca, Lori ;

Tardif, Jean-Claude ;

Waters, David D. ;

Shear, Charles L. ;

Revkin, James H. ;

Buhr, Kevin A. ;

Fisher, Marian R. ;

Tall, Alan R. ;

Brewer, Bryan .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122

[2] Lipoprotein management in patients with cardiometabolic risk [J].

Brunzell, John D. ;

Davidson, Michael ;

Furberg, Curt D. ;

Goldberg, Ronald B. ;

Howard, Barbara V. ;

Stein, James H. ;

Witztum, Joseph L. .

DIABETES CARE, 2008, 31 (04) :811-822

[3] Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations [J].

Davidson, MH ;

Maki, KC ;

Pearson, TA ;

Pasternak, RC ;

Deedwania, PC ;

McKenney, JM ;

Fonarow, GC ;

Maron, DJ ;

Ansell, BJ ;

Clark, LT ;

Ballantyne, CM .

AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (04) :556-563

[4] Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels [J].

Davidson, Michael H. ;

McKenney, James M. ;

Shear, Charles L. ;

Revkin, James H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (09) :1774-1781

[5] Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey [J].

Ford, ES ;

Giles, WH ;

Dietz, WH .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (03) :356-359

[6]

Grundy SM, 2004, ARTERIOSCL THROM VAS, V24, pE149, DOI 10.1161/01.ATV.0000133317.49796.0E

[7] Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials [J].

Hsia, Judith ;

Otvos, James D. ;

Rossouw, Jacques E. ;

Wu, LieLing ;

Wassertheil-Smoller, Sylvia ;

Hendrix, Susan L. ;

Robinson, Jennifer G. ;

Lund, Bernedine ;

Kuller, Lewis H. .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (09) :1666-1671

[8] Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women [J].

Hulley, S ;

Grady, D ;

Bush, T ;

Furberg, C ;

Herrington, D ;

Riggs, B ;

Vittinghoff, E .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (07) :605-613

[9] Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment [J].

Kastelein, John J. P. ;

van der Steeg, Wim A. ;

Holme, Ingar ;

Gaffney, Michael ;

Cater, Nilo B. ;

Barter, Philip ;

Deedwania, Prakash ;

Olsson, Anders G. ;

Boekholdt, S. Matthijs ;

Demicco, David A. ;

Szarek, Michael ;

LaRosa, John C. ;

Pedersen, Terje R. ;

Grundy, Scott M. .

CIRCULATION, 2008, 117 (23) :3002-3009

[10] Non-high-density lipoprotein cholesterol: The forgotten therapeutic target [J].

Maki, KC ;

Galant, R ;

Davidson, MH .

AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (9A) :59K-64K

← 1 2 →